Related Experiment Video
Updated: Jun 6, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
Promising pharmacotherapy on the horizon for nicotine dependence
1Dr. Berrettini is the Karl E. Rickels Professor of Psychiatry, Director, Center for Neurobiology and Behavior, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Abstract:
Nicotine dependence pharmacotherapy is important to psychiatrists, as epidemiological studies indicate that a majority of individuals with schizophrenia or affective disorders are daily smokers. The epidemiology of nicotine dependence and the efficacy of nicotine dependence pharmacotherapies are reviewed briefly. Then, novel pharmacotherapies for which FDA approval is expected next year are described.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Drug Abuse and Addiction: Pharmacological Phenomena
Drug Dependence
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
